The Expanding Treatment Armamentarium for EGFR-mutated NSCLC: Case-Based Strategies for the Community-Based Clinician

The Expanding Treatment Armamentarium for EGFR-mutated NSCLC: Case-Based Strategies for the Community-Based Clinician is organized by Healio, Cornerstone Medical Education.

Release date: May 12, 2025
Expiration date: May 12, 2026

Description:
This educational initiative is targeted to the collaborative interprofessional oncology care team including Medical Oncologists, Advanced Practice Providers (Nurse Practitioners and Physician Assistants), Nurses and Pharmacists. Designed as a dynamic, expert-driven webinar, this activity will provide learners with a data driven, case-based overview of the established and expanding role of novel agents, such as bispecific monoclonal antibodies (mAbs), in combination with third-generation TKIs and/or chemotherapy in the EGFRm mNSCLC management calculus.  This CE program will emphasize the latest data, regulatory approvals, and clinical nuances in differentiating between newly-approved agents and regimens in the 1st and 2nd line EGFRm mNSCLC treatment setting on a patient-centric basis.

Learning Objectives:

• Review the role of EGFR mutations in NSCLC tumorigenesis and appraise molecular testing guidelines to identify EGFR biomarkers that will ultimately guide targeted therapy decisions.
• Evaluate the established and evolving clinical trial evidentiary base for novel monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) in EGFR-mutated metastatic NSCLC (EGFRm mNSCLC), emphasizing the practice-changing potential of these agents in 1st and 2nd line treatment settings.
• Summarize the latest  NCCN guideline recommendations for the treatment of EGFRm mNSCLC, with a specific focus on exon 19 deletions, exon 21 L858R substitutions, and exon 20 insertions.
• Work with your team to design individualized, evidence-driven treatment plans for patients with EGFRm mNSCLC, highlighting clinical nuances between available agents in 1st and 2nd line treatment.
• Apply the principles of shared decision making to real-world patient cases, focusing on the role of the interprofessional and interdisciplinary team in the mitigation and management of treatment-related adverse events for patients with EGFRm mNSCLC.